Gabapentin

Pre-clinicalUNKNOWN
0 watching 0 views this week๐Ÿ’ค Quiet
22
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pruritus

Conditions

Pruritus, Uremia

Trial Timeline

Oct 1, 2005 โ†’ Mar 1, 2006

About Gabapentin

Gabapentin is a pre-clinical stage product being developed by Pfizer for Pruritus. The current trial status is unknown. This product is registered under clinical trial identifier NCT00577967. Target conditions include Pruritus, Uremia.

Hype Score Breakdown

Clinical
5
Activity
2
Company
9
Novelty
2
Community
1

Clinical Trials (10)

NCT IDPhaseStatus
NCT01441401Pre-clinicalCompleted
NCT00620555Phase 3Completed
NCT00603473Phase 3Completed
NCT00567268Pre-clinicalCompleted
NCT00659100Phase 3Completed
NCT00577967Pre-clinicalUNKNOWN
NCT00533455Phase 3Terminated
NCT00137735Phase 3Completed
NCT00644748ApprovedCompleted
NCT00169013ApprovedCompleted

Competing Products

20 competing products in Pruritus

See all competitors
ProductCompanyStageHype Score
Nalmefene + PlaceboTharimmunePhase 2
44
SHR0410Jiangsu Hengrui MedicinePhase 1
33
SHR0410 + PlaceboJiangsu Hengrui MedicinePhase 1
33
DNK333 5 mg + Placebo to 5 mg + DNK333 25 mg + Placebo to 25 mg + DNK333 100 mg + Placebo to 100 mg + Betamethasone 4 mg + DNK333 1mg + Placebo to 1mgNovartisPhase 2
52
MR13A9 + PlaceboKissei PharmaceuticalPhase 3
76
MR13A9 + PlaceboKissei PharmaceuticalPhase 2
51
Dupilumab + Placebo + Fexofenadine (loratadine if not available)SanofiPhase 3
76
BLU-5937 + PlaceboGSK plcPhase 2
51
Dupilumab 300Mg Solution for InjectionRegeneron PharmaceuticalsPhase 2
51
REGN846Regeneron PharmaceuticalsPhase 1/2
40
HSK21542 + PlaceboHaisco Pharmaceutical GroupPhase 2
49
Stage I:HSK21542 0.05 ฮผg/kg + Stage I:HSK21542 0.15 ฮผg/kg + Stage I:HSK21542 0.30 ฮผg/kg + Stage I:HSK21542 0.80 ฮผg/kg + Stage II:HSK21542 0.3 ฮผg/kg + Stage II:HSK21542 0.6 ฮผg/kgHaisco Pharmaceutical GroupPhase 2
49
HSK21542 tablet + PlaceboHaisco Pharmaceutical GroupPhase 2
49
HSK21542 + PlaceboHaisco Pharmaceutical GroupPhase 3
74
nalbuphine HCl ERTrevi TherapeuticsPhase 2/3
60
Nalbuphine HCL ERTrevi TherapeuticsPhase 1
28
nalbuphine HCl ER tablets 60 mg BID + nalbuphine HCl ER tablets 120mg BID + Placebo tablets BIDTrevi TherapeuticsPhase 2/3
60
VLY-686 + PlaceboVanda PharmaceuticalsPhase 2
44
VLY-686 + PlaceboVanda PharmaceuticalsPhase 1
25
Serlopitant + PlaceboVyne TherapeuticsPhase 2
44